Evidence map›Paper›PMID 37517864›Full record

ArticleCytotherapy2023

Corrigendum to ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa [Cytotherapy 25 (2023) 782-788/1562].

Kathrin Dieter, Elke Niebergall-Roth, Cristina Daniele, Silvia Fluhr, Natasha Y Frank, Christoph Ganss, Dimitra Kiritsi, John A McGrath, Jakub Tolar, Markus H Frank and 1 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Kathrin DieterRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Elke Niebergall-RothTICEBA GmbH, Heidelberg, Germany.
Cristina DanieleRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Silvia FluhrRHEACELL GmbH & Co. KG, Heidelberg, Germany.
Natasha Y FrankDepartment of Medicine, VA Boston Healthcare System, Boston, Massachusetts, USA; Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Transplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Christoph GanssRHEACELL GmbH & Co. KG, Heidelberg, Germany; TICEBA GmbH, Heidelberg, Germany.
Dimitra KiritsiDepartment of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
John A McGrathSt John's Institute of Dermatology, Guy's Hospital, King's College London, London, UK.
Jakub TolarDivision of Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, University of Minnesota M Health Fairview Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Markus H FrankTransplant Research Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
Mark A KluthRHEACELL GmbH & Co. KG, Heidelberg, Germany; TICEBA GmbH, Heidelberg, Germany. Electronic address: andreas.kluth@ticeba.com.
Rheacell (Germany) · DEBoston Children's Hospital · USEdith Cowan University · AUGuy's Hospital · GBUniversity of Freiburg · DEUniversity of Minnesota · US

Funding

Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis BullosaR01AR063070 · NIAMS · UNIVERSITY OF MINNESOTA · PI Mark J Osborn, Jakub Tolar · 2013 to 2026
$4.5M
NIAMS NIH HHS R01 AR063070
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37517864
PMCPMC10581616
OpenAlexW4385370929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.